Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPraxis partners with Remagine Labs to develop transdermal patch for ulixacaltamide
Filed July 7, 2026 · Period ending July 7, 2026 · ~1 min read
Key Changes
-
high
Praxis entered a research collaboration with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide in essential tremor, complementing its existing oral formulation program.
Item 8.01 verify on EDGAR → -
high
The transdermal option aims to broaden the addressable patient population, strengthen competitive positioning, and extend the long-term value of the ulixacaltamide franchise.
Item 8.01 verify on EDGAR → -
medium
Praxis made an equity investment in Remagine Labs; the filing discloses no amount, ownership percentage, or Remagine's public/private status — materiality is unknowable from this 8-K.
Item 8.01 verify on EDGAR →
Summary
Praxis has entered a research collaboration with Remagine Labs to develop a transdermal patch delivery system for ulixacaltamide, its drug candidate for essential tremor. The partnership will apply Remagine's electronically controlled iontophoretic platform to enable multi-day transdermal dosing, adding a second delivery option alongside the oral formulation Praxis is already developing. The company states the transdermal approach is intended to expand the patient population ulixacaltamide can reach and strengthen its competitive position in the essential tremor market.
For retail holders, this collaboration represents a strategic effort to maximize the commercial potential of ulixacaltamide by addressing patients who may not be suitable candidates for oral therapy. Praxis has also made an equity investment in Remagine, but the filing discloses no dollar amount, ownership percentage, or whether Remagine is public or private — so the investment's materiality is unknowable from this 8-K. The transdermal program adds a development pathway that could extend the franchise's value if successful, though it also introduces execution risk and timeline uncertainty inherent in any new formulation development.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
A transdermal option is intended to broaden the population ulixacaltamide can reach, while strengthening ulixacaltamide’s competitive positioning and extending the long-term value of the franchise.
The transdermal delivery option is designed to expand the addressable patient population for ulixacaltamide beyond those who can use the oral formulation. This approach aims to improve the drug's competitive position in the essential tremor market and extend the commercial value of the ulixacaltamide franchise over the long term.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 9, 2026 · How we verify